Announcements
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
- Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
- Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
- Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
More ▼
Key statistics
As of last trade AnaptysBio Inc (0HFQ:LSE) traded at 21.20, -22.26% below its 52-week high of 27.27, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 21.20 |
Average volume | 186.33 |
---|---|
Shares outstanding | 26.76m |
Free float | 26.66m |
P/E (TTM) | -- |
Market cap | 574.60m USD |
EPS (TTM) | -6.07 USD |
Data delayed at least 20 minutes, as of Apr 17 2024 14:32 BST.
More ▼